Clinuvel Pharmaceuticals Limited

Equities

CUV

AU000000CUV3

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
14.36 AUD +1.27% Intraday chart for Clinuvel Pharmaceuticals Limited +5.05% -10.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Clinuvel Pharmaceuticals Launches Share Buyback Program MT
Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 MT
Clinuvel Pharmaceuticals Limited announces an Equity Buyback for 1,500,000 shares, representing 2.99% of its issued share capital. CI
Clinuvel Pharmaceuticals Limited authorizes a Buyback Plan. CI
Clinuvel Reports Positive Results in SCENESSE Study MT
Transcript : Clinuvel Pharmaceuticals Limited, H1 2024 Earnings Call, Feb 22, 2024
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Clinuvel Pharmaceuticals Limited Announces Change to Registered Office CI
Clinuvel Doses First Patient in Phase 3 Trial of Vitiligo Treatment MT
Transcript : Clinuvel Pharmaceuticals Limited - Special Call
Clinuvel Pharmaceuticals Limited Announces Board Changes CI
Clinuvel Pharmaceuticals Teams Up With Vitiligo Experts to Assess Scenesse MT
Transcript : Clinuvel Pharmaceuticals Limited, 2023 Earnings Call, Aug 29, 2023
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023 CI
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Clinuvel Pharmaceuticals Secures Supply Contract for Porphyria Medication with the US Department of Veterans Affairs MT
Clinuvel Pharmaceuticals Secures Patents for Melanocortins for Treatment of Central Nervous System Disorders MT
Clinuvel Pharmaceuticals Treats First Patient in Phase Two Stroke Trial MT
Clinuvel Pharmaceuticals Limited Announces Technical Note - CUV803 Study and AIS CI
Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with PRENUMBRA Instant CI
Clinuvel Pharmaceuticals Limited Present DNA Repair Data At American Academy of Dermatology Meeting CI
Clinuvel Pharmaceuticals Says It Has No Deposits at Silicon Valley Bank MT
Clinuvel Pharmaceuticals Launches Skin Protection Product MT
Clinuvel Launches Cyacle, Next Generation Solar Care CI
CLINUVEL Launches First Dermatocosmetic Product CI
Chart Clinuvel Pharmaceuticals Limited
More charts
Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a rare, genetic metabolic disorder, erythropoietic protoporphyria (EPP). The Company's pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural a-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.36 AUD
Average target price
25.01 AUD
Spread / Average Target
+74.16%
Consensus
  1. Stock
  2. Equities
  3. Stock Clinuvel Pharmaceuticals Limited - Australian S.E.
  4. News Clinuvel Pharmaceuticals Limited
  5. Clinuvel Pharmaceuticals Verifies Safety, Tolerability of Neurological Drug on Stroke Patients